PERSPECTIVE THERAPEUTICS, INC. Operating Lease, Expense
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Operating Lease, Expense of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-10
- PERSPECTIVE THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-06-30 was $300.00K, a 0.00% change year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-03-31 was $300.00K, a 0.00% change year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-12-31 was -$700.00K, a 333.33% decline year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-09-30 was $300.00K, a 0.00% change year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. operating lease, expense for fiscal 2025 was $100.00K, a 87.50% decline from fiscal 2024.
- PERSPECTIVE THERAPEUTICS, INC. operating lease, expense for fiscal 2024 was $800.00K, a 700.00% increase from fiscal 2023.
- PERSPECTIVE THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $100.00K.
- PERSPECTIVE THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-10 | $600.00K 10-Q · filed 2026-08-10 | -$100.00K derived: sum of 3 quarters · filed 2026-08-10 | $200.00K derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-11 | -$400.00K derived: sum of 2 quarters · filed 2026-05-11 | -$100.00K derived: sum of 3 quarters · filed 2026-05-11 | $200.00K derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | -$700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$400.00K derived: sum of 2 quarters · filed 2026-03-16 | -$100.00K derived: sum of 3 quarters · filed 2026-08-10 | $100.00K 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-10 | $600.00K derived: sum of 2 quarters · filed 2026-08-10 | $800.00K 10-Q · filed 2025-11-10 | $1.20M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-10 | $600.00K 10-Q · filed 2026-08-10 | $900.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.20M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-11 | $600.00K derived: sum of 2 quarters · filed 2026-05-11 | $900.00K derived: sum of 3 quarters · filed 2026-05-11 | $1.10M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $600.00K derived: sum of 2 quarters · filed 2026-03-16 | $800.00K derived: sum of 3 quarters · filed 2026-03-16 | $800.00K 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-10 | $500.00K derived: sum of 2 quarters · filed 2025-11-10 | $500.00K 10-Q · filed 2025-11-10 | $500.00K derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $200.00K 10-Q · filed 2025-08-13 | $300.00K 10-Q · filed 2025-08-13 | $300.00 10-Q · filed 2024-08-13 | $200.00K derived: sum of 3 quarters · filed 2025-08-13 | $400.00K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2025-05-12 | $200.00K derived: sum of 3 quarters · filed 2025-05-12 | $200.00K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | -$300.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-03-28 | -$100.00K derived: sum of 2 quarters · filed 2025-03-28 | -$100.00K derived: sum of 3 quarters · filed 2025-03-28 | $100.00K 10-K/A · filed 2025-03-28 | $97.00K 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $200.00K 10-Q · filed 2024-11-12 | $155.00K 10-Q · filed 2023-11-14 | $200.00K derived: sum of 2 quarters · filed 2024-11-12 | $400.00K 10-Q · filed 2024-11-12 | $355.00K 10-Q · filed 2023-11-14 | $121.00K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $86.00K 10-Q · filed 2023-08-11 | $0.00 10-Q · filed 2024-08-13 | $200.00K 10-Q · filed 2023-08-11 | -$79.00K derived: sum of 3 quarters · filed 2024-08-13 | $0.00 derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | $114.00K 10-Q · filed 2023-05-15 | -$79.00K derived: sum of 2 quarters · filed 2024-05-15 | $0.00 derived: sum of 3 quarters · filed 2024-05-15 | $77.00K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$79.00K derived: 10-K 6 month − 10-Q 3 month · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | $161.00K 10-KT · filed 2023-05-01 | $77.00K derived: sum of 3 quarters · filed 2024-03-28 | $155.00K derived: sum of 4 quarters · filed 2024-03-28 | |||
| 2022-09-30 | $79.00K 10-Q · filed 2023-11-14 | $156.00K derived: sum of 2 quarters · filed 2023-11-14 | $235.00K 10-Q · filed 2023-11-14 | $313.00K derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $77.00K 10-Q · filed 2023-08-11 | $156.00K 10-Q · filed 2023-08-11 | $234.00K derived: sum of 3 quarters · filed 2023-08-11 | $0.00 10-K · filed 2024-03-28 | $312.00K 10-K · filed 2022-09-28 | |||
| 2022-03-31 | $78.00K 10-Q · filed 2023-05-15 | $157.00K derived: sum of 2 quarters · filed 2023-05-15 | $235.00K 10-Q · filed 2022-05-13 | $312.00K derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $79.00K 10-Q · filed 2022-02-09 | $156.00K 10-Q · filed 2022-02-09 | $234.00K derived: sum of 3 quarters · filed 2023-05-01 | $309.00K derived: sum of 4 quarters · filed 2023-05-01 | ||||
| 2021-09-30 | $78.00K 10-Q · filed 2022-11-14 | $77.00K 10-Q · filed 2021-11-10 | $155.00K derived: sum of 2 quarters · filed 2023-05-01 | $230.00K derived: sum of 3 quarters · filed 2023-05-01 | $306.00K derived: sum of 4 quarters · filed 2023-05-01 | |||
| 2021-06-30 | $77.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2023-05-01 | $152.00K derived: sum of 2 quarters · filed 2023-05-01 | $228.00K derived: sum of 3 quarters · filed 2023-05-01 | $304.00K 10-KT · filed 2023-05-01 | ||||
| 2021-03-31 | $75.00K 10-Q · filed 2022-05-13 | $151.00K derived: sum of 2 quarters · filed 2022-05-13 | $227.00K 10-Q · filed 2022-05-13 | $298.00K derived: sum of 4 quarters · filed 2023-05-01 | ||||
| 2020-12-31 | $76.00K 10-Q · filed 2022-02-09 | $152.00K 10-Q · filed 2022-02-09 | $223.00K derived: sum of 3 quarters · filed 2023-05-01 | $296.00K derived: sum of 4 quarters · filed 2023-05-01 | ||||
| 2020-09-30 | $73.00K 10-Q · filed 2021-11-10 | $147.00K derived: sum of 2 quarters · filed 2023-05-01 | $220.00K derived: sum of 3 quarters · filed 2023-05-01 | $293.00K derived: sum of 4 quarters · filed 2023-05-01 | ||||
| 2020-06-30 | $74.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2023-05-01 | $147.00K derived: sum of 2 quarters · filed 2023-05-01 | $220.00K derived: sum of 3 quarters · filed 2023-05-01 | $294.00K 10-KT · filed 2023-05-01 | ||||
| 2020-03-31 | $73.00K 10-Q · filed 2021-05-14 | $146.00K derived: sum of 2 quarters · filed 2021-05-14 | $220.00K 10-Q · filed 2021-05-14 | |||||
| 2019-12-31 | $73.00K 10-Q · filed 2021-02-09 | $147.00K 10-Q · filed 2021-02-09 | ||||||
| 2019-09-30 | $73.00K 10-Q · filed 2020-11-13 | |||||||
| 2019-06-30 | $285.00K 10-K · filed 2021-09-27 | |||||||
| 2018-06-30 | $285.00K 10-K · filed 2020-09-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |